TY - JOUR
T1 - Mutations in Glucose Transporter 9 Gene SLC2A9 Cause Renal Hypouricemia
AU - Matsuo, Hirotaka
AU - Chiba, Toshinori
AU - Nagamori, Shushi
AU - Nakayama, Akiyoshi
AU - Domoto, Hideharu
AU - Phetdee, Kanokporn
AU - Wiriyasermkul, Pattama
AU - Kikuchi, Yuichi
AU - Oda, Takashi
AU - Nishiyama, Junichiro
AU - Nakamura, Takahiro
AU - Morimoto, Yuji
AU - Kamakura, Keiko
AU - Sakurai, Yutaka
AU - Nonoyama, Shigeaki
AU - Kanai, Yoshikatsu
AU - Shinomiya, Nariyoshi
PY - 2008/12/12
Y1 - 2008/12/12
N2 - Renal hypouricemia is an inherited disorder characterized by impaired renal urate (uric acid) reabsorption and subsequent low serum urate levels, with severe complications such as exercise-induced acute renal failure and nephrolithiasis. We previously identified SLC22A12, also known as URAT1, as a causative gene of renal hypouricemia. However, hypouricemic patients without URAT1 mutations, as well as genome-wide association studies between urate and SLC2A9 (also called GLUT9), imply that GLUT9 could be another causative gene of renal hypouricemia. With a large human database, we identified two loss-of-function heterozygous mutations in GLUT9, which occur in the highly conserved "sugar transport proteins signatures 1/2." Both mutations result in loss of positive charges, one of which is reported to be an important membrane topology determinant. The oocyte expression study revealed that both GLUT9 isoforms showed high urate transport activities, whereas the mutated GLUT9 isoforms markedly reduced them. Our findings, together with previous reports on GLUT9 localization, suggest that these GLUT9 mutations cause renal hypouricemia by their decreased urate reabsorption on both sides of the renal proximal tubules. These findings also enable us to propose a physiological model of the renal urate reabsorption in which GLUT9 regulates serum urate levels in humans and can be a promising therapeutic target for gout and related cardiovascular diseases.
AB - Renal hypouricemia is an inherited disorder characterized by impaired renal urate (uric acid) reabsorption and subsequent low serum urate levels, with severe complications such as exercise-induced acute renal failure and nephrolithiasis. We previously identified SLC22A12, also known as URAT1, as a causative gene of renal hypouricemia. However, hypouricemic patients without URAT1 mutations, as well as genome-wide association studies between urate and SLC2A9 (also called GLUT9), imply that GLUT9 could be another causative gene of renal hypouricemia. With a large human database, we identified two loss-of-function heterozygous mutations in GLUT9, which occur in the highly conserved "sugar transport proteins signatures 1/2." Both mutations result in loss of positive charges, one of which is reported to be an important membrane topology determinant. The oocyte expression study revealed that both GLUT9 isoforms showed high urate transport activities, whereas the mutated GLUT9 isoforms markedly reduced them. Our findings, together with previous reports on GLUT9 localization, suggest that these GLUT9 mutations cause renal hypouricemia by their decreased urate reabsorption on both sides of the renal proximal tubules. These findings also enable us to propose a physiological model of the renal urate reabsorption in which GLUT9 regulates serum urate levels in humans and can be a promising therapeutic target for gout and related cardiovascular diseases.
UR - https://www.scopus.com/pages/publications/57049174486
UR - https://www.scopus.com/pages/publications/57049174486#tab=citedBy
U2 - 10.1016/j.ajhg.2008.11.001
DO - 10.1016/j.ajhg.2008.11.001
M3 - Article
C2 - 19026395
AN - SCOPUS:57049174486
SN - 0002-9297
VL - 83
SP - 744
EP - 751
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 6
ER -